Why GlaxoSmithKline plc Should Lag The FTSE 100 This Year

GlaxoSmithKline plc (LON: GSK) has been slipping. Is there further to go?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskAfter a fall of 12% to 1,423p since the start of 2014, the chances of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) shares beating the FTSE 100 by year-end are looking pretty slim, even though the index itself has fallen 1%.

So what’s going wrong?

Stalling earnings

The price slipped in July, when the company’s interim report told us to expect full-year core earnings per share only in line with 2013’s, and a couple of brokers have subsequently downgraded their target price for the shares.

The investigation into bribery allegations in China has taken its toll too, and many will be pleased that the company got away with a relatively light punishment. Announced on 19 September, the Chinese court found that Glaxo’s Chinese subsidiary had illegally “offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel“, and was handed a fine of £297m.

That was more lenient than many had feared, and the share price actually perked up a little on the day of the announcement. In fact, it was a good deal less than the $3bn the company had to pay in 2012 after confessing to having illegally marketed drugs in the USA.

Selling pharmaceuticals is a business that clearly has its dirty side, and with allegations of dodgy practices in a handful of other countries too, fears of further penalties are surely helping keep the share price down.

Bright future?

But is there an upside?

With the share price down, we’re looking at a forward P/E of 15. That’s a fraction above the long-term FTSE average, but Glaxo has been paying dividends significantly above average. Last year shareholders enjoyed a 4.8% yield, and there’s 5.6% forecast for this year.

The problem, though, is that it will not be well covered. Although Glaxo expects core EPS to be flat, analysts are forecasting a 19% fall in the overall figure, and that would leave the dividend covered only 1.18 times. Cover based on 2015 forecasts would recover a little, to 1.19 times, and Glaxo can meet its dividends from its own resources over a couple of flat years — but longer term, we need to see stronger earnings.

The company is in a transition phase at the moment after patent expiry has hit sales of a number of key drugs, but there are some promising new candidates coming along including new launches of diabetes and cancer drugs.

Long-term confidence

At interim time, chief executive Sir Andrew Witty did say that “…we remain confident in GSK’s medium and long-term growth prospects and in our strategy to generate sustainable sales growth“.

Overall, then, I don’t think there are any long-term worries — but we’ll need to see if any further dodgy-dealing investigations emerge.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »